CD4 News and Research

RSS

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

A team of scientists from Immanuel Kant Baltic Federal University with their colleagues from the Institute of Ecology and Genetics of Microorganisms of the Ural Branch of the Russian Academy of Sciences (Perm) studied the effect of trophoblastic β1-glycoprotein in the blood of pregnant women on pro-inflammatory immune cells.

10 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

HIV: New therapeutic approach to restore the effectiveness of immune cells

Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique has identified a therapeutic approach to restore the effectiveness of immune cells.

8 Feb 2021

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Novel biomarker may help identify which pancreatic cancer patients respond to CD40 agonists

Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight.

4 Feb 2021

POSTECH researchers discover mechanism behind intestinal epithelial lymphocyte differentiation

The intestine harbors the largest number of immune cells in our body. Since the intestine is constantly exposed to various antigens like bacteria and food, appropriate induction of gut immune cells plays a pivotal role in gut homeostasis.

4 Feb 2021

Experimental intranasal influenza vaccine produces durable immune response

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.

3 Feb 2021

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

A new preprint examines Long COVID-19, aiming to identify the underlying immunologic status in such patients.

3 Feb 2021

Researchers explore adaptive immunity against human coronaviruses

A recent study shows that long-term adaptive immunity to endemic coronaviruses is widespread, but low in magnitude, and that it shares phenotypic features of spike-specific antibodies and T cell memory across all tested coronaviruses.

29 Jan 2021

Researchers develop ‘next-generation vaccine platform’ against SARS-CoV-2

Researchers have designed a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG (Oligodeoxyribonucleotides) adjuvant.

29 Jan 2021

Study provides a detailed look at vulnerable sites on SARS-CoV-2

A new study led by scientists at La Jolla Institute for Immunology (LJI) suggests that T cells try to fight SARS-CoV-2 by targeting a broad range of sites on the virus--beyond the key sites on the virus's spike protein.

27 Jan 2021

People with severe COVID-19 cases may have more protective "memory" T cells

A big question on people's minds these days: how long does immunity to SARS-CoV-2 last following infection?

22 Jan 2021

FDA approves first injectable, complete regimen for HIV-1 infection in adults

The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

21 Jan 2021

High factor V levels linked to lymphopenia and weakened immunity in severe COVID-19

A new study suggests that factor V, a coagulation factor, is upregulated in a range of white blood cells in severe COVID-19. This increase is linked to the observed coagulopathy, lymphopenia and suppression of adaptive immunity in such patients.

21 Jan 2021

Lower CD4 T cell reactivity to seasonal coronaviruses found in healthcare workers with COVID-19

A new study by US-based researchers describes the results of a study on the immune response among healthcare workers, in particular, their T cell responses predating the pandemic.

19 Jan 2021

NK and T cell subsets show distinctive lung-homing receptor profiles in COVID-19 patients

A new study reveals in detail the changes that occur in peripheral blood natural killer (NK) and T cells in COVID-19.

18 Jan 2021

Analysis supports phase 3 trials of Johnson & Johnson's COVID-19 vaccine

Researchers in the Netherlands, the United States, and Belgium have presented early-stage clinical trial results demonstrating the safety and efficacy of Johnson & Johnson's vaccine candidate for coronavirus disease 2019 (COVID-19).

17 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

CD4 News and Research

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

HIV: New therapeutic approach to restore the effectiveness of immune cells

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Novel biomarker may help identify which pancreatic cancer patients respond to CD40 agonists

POSTECH researchers discover mechanism behind intestinal epithelial lymphocyte differentiation

Experimental intranasal influenza vaccine produces durable immune response

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

Researchers explore adaptive immunity against human coronaviruses

Researchers develop ‘next-generation vaccine platform’ against SARS-CoV-2

Study provides a detailed look at vulnerable sites on SARS-CoV-2

People with severe COVID-19 cases may have more protective "memory" T cells

FDA approves first injectable, complete regimen for HIV-1 infection in adults

High factor V levels linked to lymphopenia and weakened immunity in severe COVID-19

Lower CD4 T cell reactivity to seasonal coronaviruses found in healthcare workers with COVID-19

NK and T cell subsets show distinctive lung-homing receptor profiles in COVID-19 patients

Analysis supports phase 3 trials of Johnson & Johnson's COVID-19 vaccine

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News